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Until fairly recently, experience with advanced endovascular technologies, including fenestrated endovascular repair
(FEVAR), has been limited to a relatively small number of practitioners worldwide. Excellent outcomes have been
achieved by these accomplished surgeons who, at least initially, have primarily used custom-made devices constructed by
a single endograft manufacturer. Access to this technology has been limited by the skills necessary for such procedures and
by the customization process with industry partners. However, several issues are changing rapidly with FEVAR.
Increasing numbers of surgeons now have the necessary endovascular skills, and off-the-shelf endografts from several
manufacturers have become, or are becoming, available. Also, the regulatory landscape is changing with device approval in
the United States. Surgeons and patients alike are anticipating the widespread adoption of this advanced technology that
will surely beneﬁt increasing numbers of patients. Or will it? Will widespread adoption in a larger number of smaller-
volume hospitals, by less experienced surgeons, result in poor patient outcomes, or will excellent results continue with
more patients beneﬁtting from these technologic advances? These are important questions to ask before such adoption
and are the subject of this debate. (J Vasc Surg 2013;57:875-83.)PART I: FENESTRATED ENDOGRAFTS SHOULD
BE RESTRICTED TO A SMALL NUMBER OF
SPECIALIST CENTERS
Stéphan Haulon, MD, PhD, David Barillà, MD,
andMark Tyrrell, MD, Lille, France; and London, United
Kingdom
Introduction. Death as a consequence of aortic catas-
trophe is a common event among the middle-aged and
retired population and is the 12th most common cause of
death in the United States.1 Although abdominal aortic
aneurysms (AAAs) and ascending aortic aneurysms are the
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are not rare, having an estimated incidence of 10.4 cases/
100,000 person-years.2 Aortic aneurysms are generally
identiﬁed serendipitously, although AAA screening
programs are being set up in some countries. Almost all
aortic disease is symptom-free. The prevention of early
death in exchange for life-long morbidity is an unaccept-
able outcome. Primum non noceredif we are to usefully
treat aneurysms, it is self-evident that the attendant thera-
peutic risks have to be contained.
Once identiﬁed, prophylactic aneurysm repair is not
without hazard, and the risks can be shown to be related
to patient selection, operator and institutional experience,
the proportion of cases done endovascularly, and the
complexity of the repair. We will argue that these
phenomena mandate that aortic repair, particularly
complex endovascular aortic repair, should be restricted
to specialist high-volume centers.
The effect of case volume. The modern move to
centralize specialized care or high-risk procedures, or
both, to high-volume centers is generally accepted as
a positive one. That the risk of postoperative morbidity and
death after complex procedures is signiﬁcantly reduced
when performed in high-volume centers has been widely
reported.3-5 In 2000, the Leapfrog Group, an American
coalition of 150 large-volume health care purchasers,
deﬁned on the basis of clinical outcomes high-volume
centers for AAA repair as those that performed $50 elec-
tive AAA repairs per year. In 2003, they suggested that
elective AAA repairs should be referred only to high-
volume centers.6875
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starker: after elective repair of TAAA, high-volume centers
report mortality rates of 5% to 6% and paraplegia rates of
3.8% to 6.3%.7 A California statewide audit reported
a 30-day mortality rate of 22% after open elective TAAA
repair.8 Moreover, survivors of TAAA repair frequently
experience debilitating postoperative complications and all
too often experience prolonged periods of hospitalization
and rehabilitation, poor functional outcome, and appre-
ciable 1-year mortality.
It is therefore no surprise that caseload is also
a predictor of postoperative death after elective repair of
TAAAs.8 Patients with TAAAs treated at high-volume
centers demonstrate a 42% reduction in mortality.
However, the median length of stay for surviving patients
increased minimally at high-volume centers. This observa-
tion may reﬂect survival after postoperative complications
rather than the shorter length of stay associated with early
postoperative death, which is inferred by the further
ﬁnding that >40% of patients who died at low-volume
centers had lengths of stay of #24 hours. The difference
between high-volume and low-volume center outcomes
suggests differences in the perioperative management of
these patients. This ﬁnding substantiates the notion that
the early expert management of complications to satisfac-
tory resolution relates to high case volumes.
Fenestrated endografts. Although there have been
continuous improvements in the devices, ancillary equip-
ment, and technique, unsuitable anatomy (short, large,
angled, or poor-quality proximal aortic sealing zones)
continues to preclude standard infrarenal endovascular
aneurysm repair (EVAR) for a signiﬁcant subset of patients,
thereby denying them the potential advantages of the
endovascular approach.9-10 Fenestrated endografts have
been designed to extend the proximal sealing zone from
the infrarenal to the suprarenal aorta to extend the
advantages of EVAR to patients with these challenging
anatomies. However, fenestrated endovascular aneurysm
repair (FEVAR) is a demanding and complex endovascular
procedure at every stage of its use: selection, planning, and
execution. The success of FEVAR depends on appropriate
experience of the clinical team. The margins for error are
small, and the consequences of minor errors are severe.
To date, the available literature evaluating FEVAR is
exclusively provided by high-volume centers. No literature
comparison between high-volume and low-volume centers
exists. As is the case with open TAAA repair, FEVAR has
been largely relegated to high-volume centers, or at least
those centers with good outcomes and signiﬁcant activities
are the ones that have reported. Nevertheless, the feasibility
and utility of fenestrated devices for the treatment of para-
renal aneurysms is well established, and several large pub-
lished series have claimed satisfactory intermediate-term
outcomes. A recent literature review indicates that FEVAR
can be performed with a 30-day mortality rate of 2.1%
(95% conﬁdence interval, 1.2%-3.7%),11 which is compa-
rable to the 2.7% rate reported after conventional EVAR
and at least equal to the 2.9% rate reported after equivalentopen surgery in highly selected patients undergoing
surgery in specialist high-volume centers.12,13
That the results of treatment for more challenging
aneurysms using complex and novel technologies should
be superﬁcially better than those for “standard” EVAR is
counterintuitive. The likely explanation is that all of the
series included in the systematic review were published by
high-volume centers. We contend therefore, that only
these centers of excellence are likely to obtain such favor-
able outcomes with FEVAR and that they succeed in doing
so speciﬁcally because of their focus, facilities, and accumu-
lated experience. Simply put, it is essential to be abreast of
the continuous development of this evolving technology
and imaging and have a high volume of varied pararenal
AAAs to treat in order to form a basis for good case selec-
tion and planning and have sufﬁcient familiarity with the
technologic platform and the expanded armamentarium
required to overcome the learning curve.
Planning FEVAR. The preoperative planning of all
EVAR procedures is a foundation stone of successful
EVAR in general, and it is all the more critical for FEVAR.
Detailed planning that requires a substantial level of expe-
rience and expertise is necessary to allow the manufacture
of devices where the fenestrations align with their respec-
tive target vessels. This speciﬁcally demands the skilled
use of three-dimensional (3D) workstations (Fig 1). All
of the following are required to design custom-made
endografts speciﬁc to individual anatomies14,15:
d An assessment of proximal and distal sealing zones
(size, surface, angulation);
d The gap between the partially and fully deployed
endograft and the visceral artery-bearing aortic wall;
d The longitudinal distances between target vessels and
angulations of and radial positions between target
vessels; and
d An estimate of vessel wall calciﬁcation and likely distor-
tion (or not) while using stiff wires, sheaths, and devices.
Inexperienced clinicians may be tempted to delegate
the planning phase to graft manufacturers’ planning
centers. This is a risky strategy because, although techni-
cally accurate planning will be provided, it will be devoid
of clinical judgment and compromise. Such grafts may be
a “true ﬁt” but prove impossible to implant! Nevertheless,
consultative engagement with (rather than delegation to)
planning centers provides invaluable insights regarding
device design limitations and should be considered manda-
tory for new adopters and later used as an expert resource
for planning the more complex repairs. Used irresponsibly,
planning centers can become a way for inexperienced
physicians to gain access to a technique that they never fully
control if they practice outside high-volume centers.
The development of FEVAR and imaging modali-
ties. Fenestrated endografts have been in a state of constant
technologic development since the ﬁrst device was
implanted in the late 1990s. The design has evolved from
being a modular bifurcated endograft with nonreinforced
Fig 1. A, Coronal maximum-intensity projection shows a reconstruction of a juxtarenal aneurysm. B, A four-vessel
fenestrated endograft is designed by performing various reconstructions with a three-dimensional workstation,
including a stretch curved planar reconstruction, to accurately measure the length between the target vessels.
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component with reinforced fenestrations and a separate
bifurcated extension below. Even the choice of bridging
stent has changed: we now use balloon-expandable covered
stents rather than balloon-expandable uncovered stents.16
The ﬁrst devices with integral side branches were intro-
duced in 2004, followed by internal iliac branches and arch
fenestrations in 2005. Low-proﬁle devices became available
in 2010. The delivery system has also been modiﬁed toinclude a “diameter-reducing tie” system, allowing partial
deployment of the device to facilitate manipulation and
repositioning of the fenestration-bearing component. More
recently, preloaded wires and catheters have been posi-
tioned across the fenestrations to eliminate the step of
fenestration cannulation, which shortens the procedure by
removing one step from the process.
There has also been continuous improvement in the
infrastructure required to perform FEVAR. The initial cases
Fig 2. A, Anteroposterior and (B) lateral ﬂuoroscopic views with fusion are required to access the left renal artery and
the visceral vessels through their respective fenestrations. C, The completion angiogram shows patent target vessels and
an excluded aneurysm.
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achieved using simple axial imaging. However, it rapidly
became clear that 3D workstations with centerline-of-
ﬂow reconstructions are essential for accurate planning.
In addition, case complexity mandates high-quality opera-
tive imaging and display as well as a good operating theater
environment. This has led to the use of hybrid operative
rooms, successively upgraded with ﬂat panel detectors
and fusion imaging software (Fig 2). All of these evolutions
have made the use of FEVAR technology quicker and
easier but have not replaced the need for considerable plan-
ning and operative experience.
In 2004, Cate et al17 recognized the need for dedi-
cated hybrid rooms for advanced endovascular procedures.
This novel concept combines advanced imaging systems
with an open surgical environment. In 2010, an expert
advisory group representing the Royal College of Radiolo-
gists, the British Society of Interventional Radiology, the
Vascular Society of Great Britain and Ireland, the Vascular
Anaesthesia Society of Great Britain and Ireland, and the
Committee on the Safety of Devices, in association with
the Medicines and Healthcare products Regulatory Agency
(MHRA), was set up to provide guidance for those centers
that have or are currently establishing an EVAR service.18
One of the prescribed essential elements for a dedicated
EVAR facility is high-quality imaging equipment to facili-
tate accurate endograft positioning and deployment to
avoid covering important vessels and compromising blood
ﬂow to essential organs such as the brain, the upper limb,
gut, or kidneys.
The intraoperative management of this imaging equip-
ment requires speciﬁc training for the operators (surgeons,
radiologists, and radiographers). Interventionalists require
a detailed knowledge of the ﬂuoroscopic options, including
imaging settings, angulation, radiation exposure, andprotection. In 2011, Dijkstra et al19 evaluated the use of
intraoperative guidance by means of C-arm cone-beam
computed tomography (CBCT) and the use of postopera-
tive CBCT to assess for successful aneurysm exclusion in
FEVAR and concluded that CBCT is a valuable addition
to complicated aortic interventions such as FEVAR.
CBCT is a potentially useful tool in the intraoperative
use of “fusion imaging,” which is a signiﬁcant evolution
of the established concept of roadmapping. In fusion
imaging, ﬂuoroscopy images are overlaid on CT images.
Kobeiter et al20 have conﬁrmed the value of these advanced
imaging softwares. They reported a case of thoracic endo-
vascular aortic repair using fusion imaging without the
need for any operative contrast injection.
We should emphasize that these facilities are essentials,
not luxuries, but they do come at considerable expense!
The learning curve associated with the effective use
of fenestrated endografts. For individual practitioners,
there is a learning curve for each of sizing and planning,
implantation, intraoperative imaging, and perioperative
patient management. During the learning phase, the endo-
vascular therapist will learn the subtleties of sizing, the use
of 3D workstations, and come to understand the inﬂuence
of varying vessel tortuosity, calciﬁcation, and caliber on the
device design and its actual implantation, as well as the
technical sequences, tricks of the trade, and salvage maneu-
vers. As important is the development of a specialist team
that includes surgeons, radiologists, anesthetists, radiogra-
phers, and nurses.
The current center of excellence exponents and their
teams have been involved in the development of the tech-
niques, have been highly focused on them, and have
acquired a range of “soft skills” required (so often impos-
sible to name, document, and disseminate) over extended
periods and many cases. This learning is reﬂected in their
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experience. All of the required stages can be taught by
proctoring, but the supervision of or observation of a hand-
ful of cases, each as a purely technical exercise, is an insuf-
ﬁcient strategy in the safe dissemination of this procedure
and all of the complexity that surrounds it. Furthermore,
considering only the device implantation, Guillou et al21
recently reported that prolonged procedure times increase
the probability of postoperative major morbidity and
deathdagain suggesting that this is not a procedure for
the uninitiated.
In short, the effective use of FEVAR demands much
more than the sum of its component parts! This is not to
indicate that new units should not adopt FEVAR, but
doing so requires a minimum annual enrollment rate (insti-
tutional and for the individual practitioner) to overcome
the learning curve.
Conclusions. There is compelling evidence that
suggests that aneurysm repair (open and EVAR) should be
performed in high-volume centers. We contend that fenes-
trated endograft repairs should only be performed in
selected high-volume centers with appropriately dedicated
teams, experience, and technical infrastructure if the results
currently reported for this technique are to persist. In our
view, it is inappropriate for a novel high-risk solution for
complex aneurysm repair in fragile patients to be generally
disseminated to occasional institutions and operators.REFERENCES
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Introduction. The value of fenestrated-branched stent
grafts (FBSGs) in the management of complex aortic
aneurysms has been clearly demonstrated from data derived
from several centers of excellence. Reduced morbidity and
mortality as well as shorter hospital length of stay have been
demonstrated to be associated with FBSGs compared with
traditional open surgery for patients with complex aortic
aneurysms. FBGSs have an even greater beneﬁt in patients
considered to be at high-risk for open repair.1-3
FBSG technology was ﬁrst introduced in 1996, with
larger series reported in 2001.4-6 Recent reports have
proven FBSG to be safe, effective, and durable, with excel-
lent long-term results. Reinterventions that were per-
formed were mostly for stenoses of branch stents and
type 1 and 3 endoleaks.7,8 Cook Medical Inc (Blooming-
ton, Ind) has been a leading manufacturer in this area for
several years, with the company reporting >4000 implanta-
tions of FBSGs worldwide. Cook recently acquired United
States Food and Drug Administration (FDA) approval for
its pararenal device in the United States and Conformité
Européene approval for its thoracoabdominal device (T-
fenestrated) in Europe. Recently, however, fenestrated-
branched technology has rapidly evolved and become
more widespread, with two more FBSG devices under
JOURNAL OF VASCULAR SURGERY
880 Haulon et al March 2013investigation or marketed outside of the United States9,10
and FBSG for thoracoabdominal and aortic arch aneurysms
being approved as investigational devices.11
Despite these recent advancements, this technology,
which was introduced >15 years ago and has been used
to treat>4000 patients worldwide, not counting the count-
less patients treated with surgeon-modiﬁed FBSG or FBSG
from other companies, continues to be restricted to only
a few centers of excellence. The intent of this report is to
argue in favor of a wider distribution of FBSG to vascular
centers and to demonstrate how any effort to restrict this
kind of technology would only compromise patient care.
WHAT KIND OF CASES, SURGEONS, AND
CENTERS ARE WE DISCUSSING HERE?
Complexity of fenestrated endovascular aneurysm
repair. Fenestrated endovascular aneurysm repair (FEVAR)
is a broad moniker that applies to a spectrum of procedures
with a wide range of complexity level and technical chal-
lenges. Juxtarenal and pararenal aneurysms, thoracoabdomi-
nal aortic aneurysms (TAAAs), and aortic arch aneurysms,
although all treated with FEVAR, are different procedures,
each associated with different procedural risks and varying
degrees of difﬁculty and complexity.
The mortality rate for open surgical repair of juxtarenal
aneurysms in contemporary series ranges between 2.5% and
2.9%,12,13 whereas contemporary results for open repair of
type IV TAAA demonstrate a twofold-higher mortality rate
of 4.4% to 5.9%.14,15 Similarly, FEVAR with repair extend-
ing above the level of the superior mesenteric artery (SMA)
or the celiac artery (suprarenal AAA or TAAA) is associated
with a higher rate of severe complications, such as spinal
cord ischemia, stroke, and renal insufﬁciency, than FEVAR
repair that stays below the SMA (juxtarenal AAA), as
a result of longer procedure times, more catheter and
wire manipulation, increased coverage of the aorta, and
the more challenging alignment of all fenestrations to the
visceral branches. FEVAR for juxtarenal aneurysms has
a mortality of 0% to 4%,1,16 whereas the mortality of
FEVAR for TAAA is reported at 6% to 10%,1,17,18 with
a risk of permanent spinal cord ischemia and permanent
renal ischemia of 2%.1
Thus, it is obvious that the challenges of a TAAA repair
with FEVAR are greater than that of pararenal aneurysm
repair, and it is the experience of the surgeon and the
center that predominantly determines the outcomes of
FEVAR in these cases.
Selection of FEVAR centers and surgeons. Young
et al19 demonstrated in their meta-analysis that a yearly
caseload of 13 AAA repairs resulted in signiﬁcantly better
survival for elective aortic aneurysm repair. Evidence
suggests that it is mostly the individual surgeon’s volume
rather than the institution’s volume that improves
outcome, although these interact to improve outcome.19
But even if one extrapolates data from such studies to
use for FEVAR, it is obvious that a yearly threshold of 13
or 15 or even 20 complex aneurysms is a number that can
be achieved in a signiﬁcant number of vascular institutionsand by a signiﬁcant number of surgeons and is not limited
to just a few centers around the world.
Excellent endovascular skills and vast experience with
EVAR are not qualities conﬁned only to surgeons at the
world’s largest aortic centers. An experienced surgeon,
skilled to perform this procedure may well be found
outside large centers. Furthermore, the mere fact that
someone practices in a large center does not guarantee
that the person performing the procedure is adequately
trained to perform it. Rather, it is more important to focus
on what speciﬁc credentials and competencies endovascular
surgeons must possess to perform these procedures and
how vascular societies should monitor these competencies
and the procedural outcomes to provide credentialing for
performing such procedures.
A minimum number of EVAR with devices of the
FBSG lineage seems obvious and mandatory. The most
important parts of a FEVAR case are the preoperative plan-
ning and intraoperative troubleshooting when unexpected
challenges are encountered during the procedure. This is
where the learning curve is steepest. Most experienced
interventionalists can navigate a wire and catheter through
a fenestration into an artery, but what gets most into
trouble is poor preoperative planning and not having the
knowledge and experience of troubleshooting when things
do not go as planned. Therefore, proper proctoring is
necessary until a requisite level of competency and comfort
are achieved in these two areas.
The FDA currently requires Cook Medical to provide
a detailed training program for physicians who will have
access to FBSG, including an extensive educational process
as well the presence of a proctor in the ﬁrst ﬁve cases per-
formed by a new operator. It is important to emphasize
that it is not the absolute number of cases that should be
used as criteria to assess competency but rather the level of
comfort one develops with the steps of the procedure as
well as the planning and troubleshooting aspect. This needs
to be individualized and may be as little as one or two cases
for some and as high as 15 to 20 cases or more for others.
Surgeons who are trained in the technique of open repair
of complex aneurysms and with adequate endovascular
skills, who meet these “requirements,” should be afforded
the opportunity to treat complex aneurysms with FEVAR.
What have we learned from centralization of
FEVAR so far? The FBSG device from Cook Medical has
been commercially available in Europe for many years. The
slow process of FDA approval in the United States,
however, mainly because of the lack of a FEVAR-
dedicated renal artery stent in the United States trial, led
to a signiﬁcant delay in commercialization. Thus, a central-
ization of FEVAR in the United States for the last decade
was inevitable. On one hand, the most positive aspect of
this centralization was that vast experience has been
collected with FEVAR in the handful of trial-participating
centers that were pioneering this technologic advance
while creating the foundation for expertise and innovation.
On the other hand, the need for FBSG was so apparent
to treat patients unﬁt for open repair or conventional
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therapy with FEVAR became large, and patients with
complex aneurysms were put on waiting lists that were
often longer than the time needed to custom manufacture
the grafts. With the annual risk of rupture estimated at
9.4% for an AAA of 5.5 to 5.9 cm, 10.2% for AAA of 6.0
to 6.9 cm, and 32.5% for AAA of $7.0 cm, it is obvious
that this not a benign waiting time, and it is not
uncommon for aneurysms to rupture while patients on
the list are waiting for their turn.20 By centralizing and
restricting access to this technology, we have done a disser-
vice to our patients.
In addition, the lack of availability and proper training
on FEVAR has led many physicians to adopt other tech-
niques out of necessity to provide treatment to their patients.
We have chosen to manufacture our own surgeon-modiﬁed
FBSGs,21,22 currently within an FDA-approved Investiga-
tional Device Exemption (IDE). However, others have
chosen to adopt off-label techniques with uncertain dura-
bility, not approved by FDA, such as the chimney-snorkel-
sandwich techniques, exposing patients to unnecessary risks
and potentially suboptimal results.23-25 Some have gone
even more to the extreme to treat thoracoabdominal aneu-
rysms with off-the-shelf devices of currently available grafts
with adventurous techniques that include up to 20 separate
pieces, which has been heavily criticized by propagators of
FEVAR.26,27
The discussion about centralization is therefore self-
limiting if, by restricting access to FEVAR technology,
we are encouraging surgeons across the globe to use tech-
niques that put patients at unnecessary increased risk,
compromise durability of repair, and are far from optimal.
What is the current status of FEVAR? FEVAR
technology is continuously evolving, thanks to the excel-
lent work of FEVAR enthusiasts such as our codebater
Dr Haulon. The recent development of off-the-shelf
fenestrated devices for juxtarenal aneurysms with pre-
loaded fenestrations eliminates time-consuming steps that
add to the complexity of FEVAR, such as branch cannu-
lation in addition to eliminating the requisite time required
to custom manufacture a device.9,28,29 This signiﬁcantly
contributes to an easier use of FBSG by more vascular
surgeons.
More and more data on FEVAR accumulate daily, sug-
gesting that FEVAR can be performed safely by surgeons
who perform even a limited number of these procedures.
Collaborators of the Global Collaborators on Advanced
Stent-Graft Techniques for Aneurysm Repair database
recently published their experience from 14 centers in the
United Kingdom that had performed >10 FEVAR proce-
dures for juxtarenal and pararenal aneurysms.16 They re-
ported a 99% procedural success rate with 0.6% of
branches unable to be cannulated intraoperatively. The
overall perioperative mortality was 4.1% and was 2.7% in
patients with renal fenestrations alone, 2.9% in patients
with renal fenestrations and a fenestration or scallop to
the SMA, and 9.4% for patients requiring incorporation
of the celiac trunk in their FBSG. This current publicationis probably the best example of how one can achieve excel-
lent results with juxtarenal FEVAR, even with limited expe-
rience, as long as the requisite endovascular skills and
comfort level with the procedure are present.
According to the suggestions of Greenberg et al,30 clas-
siﬁcation of pararenal and suprarenal aneurysms should be
performed according to the extent of the repair required,
so that aneurysms requiring four fenestrations would fall
into the type IV TAAA repair category. The United
Kingdom report that demonstrated that mortality increases
as the extent of the repair becomes more complex supports
our argument that a FEVAR with three to four fenestrations
represents a different challenge than an FEVAR with one or
two fenestrations, with or without scallop to the SMA.
We recently reported real-world data for FEVAR using
the American College of Surgeons National Surgical
Quality Improvement Program, which collects data from
>300 institutions across the United States.31 In 264
FEVAR patients randomly captured from these institu-
tions, the 30-day mortality was 0.8%, risk of any complica-
tion was18%, and the risk of any renal complication was
1.5%. Although these data are limited by the lack of infor-
mation concerning the extent of repair, they reﬂect the
excellent results achieved with FEVAR on a national scale,
which includes data from several centers across the United
States that perform FBSG in the setting of a clinical trial as
well as data from sites performing surgeon-modiﬁed FBSG.
What should the future in FEVAR look like? As
much as Dr. Haulon tries to convince us that FBSG should
be restricted to a few centers, he is in this debate a victim of
his own work on off-the-shelf devices, which signiﬁcantly
reduce the complexity of FEVAR and make it possible for
every surgeon with endovascular skills and an under-
standing of FEVAR principles to perform these procedures.
For vascular surgery to evolve and remain ahead of the
technologic advancements, any new technology should be
disseminated as widely as possible in a controlled fashion
that allows close monitoring of outcomes. Only in this way
will we be able to attract industry interest in these tech-
niques and further develop available devices. Proper
training and proctoring should be promoted and consid-
ered a prerequisite by industry and vascular societies.
The goal of the vascular societies across the world
should be to properly train physicians during their formal
training who afterwards are able to use FBSGs to perform
a two-vessel FEVAR (with or without SMA scallop) in any
vascular unit with a sufﬁcient aortic workload. We do not
need only a few centers of excellence and few “all-star
vascular surgeons” but rather a strong widespread vascular
community with access to the latest devices and technology
who possess the requisite skills and comfort level to safely
and effectively treat the many patients who can beneﬁt
from this technology in as many places across the world
as possible.
Conclusions. All vascular surgeons trained in open
aortic surgery should be able to treat open pararenal aneu-
rysms in the elective and emergency setting, and the same
should apply for FEVAR. The use of FEVAR for patients
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fenestrations and an SMA scallop should belong in the
armamentarium of all vascular surgeons who treat aortic
aneurysms. By restricting access to this technology and
not properly training our vascular surgery community, we
are doing a disservice to our patients by restricting their
access to the therapy and subjecting them to unproven
and potentially unsafe procedures.
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stent separation. Ann Vasc Surg 2013;27:110.e1-4.EDITORS’ COMMENTARYThomas L. Forbes, MD, and Jean-Baptiste Ricco, MD, PhD, London, Ontario, Canada; and Poitiers, FranceDuring the last decade, a relatively small number of centers
worldwide, including Prof Haulon’s, have gained extensive experi-
ence treating juxtarenal and suprarenal abdominal aortic aneu-
rysms with fenestrated devices (FEVAR). These pioneers shouldbe commended for the excellent outcomes they have achieved
and their contributions to continued device reﬁnement and devel-
opment. This has primarily been achieved using Cook’s (Bloo-
mington, Ind) custom-made fenestrated device platform and has
